Follitropin Delta Versus Follitropin Alfa in Indonesian Women Undergoing IUI

Comparative Clinical Outcome Between Follitropin Delta With Simplified Dosage Equivalent and Follitropin Alfa in Indonesian Women Undergoing Intrauterine Insemination

The goal of this retrospective observational study is to compare two types of follicle-stimulating hormone, follitropin delta and follitropin alfa, used for ovarian stimulation in Indonesian women undergoing intrauterine insemination (IUI) for infertility treatment. The study includes women younger than 40 years who underwent IUI at Halim Fertility Center, Indonesia, between January 2020 and December 2022.

The main questions this study aims to answer are:

• Is ovarian stimulation with a simplified follitropin delta dosing regimen associated with a different clinical pregnancy rate compared with conventional follitropin alfa treatment?
• Are the rates of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) different between the two treatment groups?

Researchers will compare women who received follitropin delta with women who received follitropin alfa as part of their fertility treatment. The study hypothesis is that a simplified follitropin delta regimen may provide comparable fertility outcomes while maintaining an acceptable safety profile compared with conventional follitropin alfa treatment.

Participants had already received one of the two ovarian stimulation treatments as part of their routine clinical care. Researchers will review their medical records and compare treatment characteristics and IUI outcomes between the two groups. The study does not assign participants to treatment because the treatments were given before the study data were analyzed.

Inclusion Criteria:

• Female age <40 years
• Undergoing intrauterine insemination (IUI) for infertility treatment
• Bilateral tubal patency
• Unexplained infertility, anovulation, and/or mild male-factor infertility
• For mild male-factor infertility: total motile sperm count (TMSC) 10-20×10^6/mL
• Baseline serum FSH <10 mIU/mL

Exclusion Criteria:

• Pre-existing medical conditions considered unsuitable for IUI treatment
• Endometriotic cyst
• Adenomyosis
• Congenital uterine anomalies
• Spontaneous ovulation
• Poor ovarian response